YOLFTbeta
Gossamer Bio Inc

Gossamer Bio Inc

GOSS · NASDAQ · Healthcare / Biotechnology

10.97USD-0.27 (-2.40%)

Price History

Full chart

Market Stats

Previous Close11.24
Open11.19
Day Range10.60 – 11.40
52-Week Range9.12 – 309.60
Volume124.14K
Market Cap66.91M
P/E (TTM)0.00
Forward P/E0.00
EPS-52.73
Dividend Yield0.00%
Beta2.00
50-Day Avg13.02
200-Day Avg72.60

About

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Faheem Hasnain
  • Employees161
  • Headquarters3115 Merryfield Row, San Diego, CA, United States, 92121, USA
  • Websitehttps://www.gossamerbio.com

Leadership

  • Mr. Faheem HasnainCo-Founder, CEO, President & Chairman · b. 1958
  • Mr. Bryan GiraudoCOO & CFO · b. 1975
  • Mr. Robert Paul Smith Jr.Chief Commercial Officer · b. 1969
  • Mr. Christian Waage J.D.Executive VP, General Counsel & Secretary · b. 1967
  • Ms. Jeanine AnthonySenior Vice President of Marketing
  • Ms. Deanna WeberExecutive Vice President of Human Resources
  • Dr. Robert F. Roscigno Ph.D.Senior Vice President of Clinical Development of Pulmonary Vascular Disease · b. 1966
  • Ms. Caryn L. PetersonChief Development Officer · b. 1959
  • Kelly DawsonSenior Vice President & Program Team Lead
  • Mr. Conor O'DonovanSenior Vice President of Regulatory Affairs

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00000000114.70M48.47M
Growth (%)----------57.74%
Cost of Revenue00297.00K3.09M4.27M5.17M4.43M4.38M4.15M1.00M
Gross Profit00-297.00K-3.09M-4.27M-5.17M-4.43M-4.38M114.70M47.47M
Gross Margin--------100.00%97.93%
Operating Expense83.00K6.65M148.70M183.05M206.31M210.96M214.16M179.37M174.62M210.72M
Operating Income-83.00K-6.65M-148.99M-186.14M-210.58M-216.12M-218.59M-183.76M-59.92M-163.25M
Operating Margin---------52.24%-336.81%
EBITDA-83.00K-6.65M-148.99M-179.45M-226.43M-209.40M-211.07M-161.92M-39.97M-158.47M
EBITDA Margin---------34.84%-326.93%
Net Income-83.00K-6.77M-146.97M-180.82M-243.36M-234.00M-229.38M-179.82M-56.53M-170.37M
Net Income Margin---------49.28%-351.49%
R&D0891.00K55.28M143.40M158.00M170.27M170.92M135.30M138.49M174.09M
R&D as % of Total Revenue--------120.74%359.17%
Interest Expense0118.00K12.00K012.67M19.44M13.88M13.51M11.52M10.99M
Interest Expense % of Total Revenue--------10.04%22.67%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets60.00K445.00K239.42M426.60M539.43M343.66M272.45M311.92M315.29M172.25M
Total Liabilities183.00K7.31M359.49M74.12M218.75M222.19M260.37M249.15M285.80M295.01M
Total Equity-123.00K-6.86M-120.07M352.49M320.68M121.46M12.08M62.77M29.49M-122.76M
Cash60.00K315.00K105.22M135.03M486.06M183.40M111.97M32.11M46.07M37.73M
Total Debt40.00K6.04M-39.55M183.73M185.24M225.74M212.46M202.88M202.91M
Net Debt-20.00K5.72M-105.22M-95.48M-302.32M1.83M113.77M180.35M156.81M165.17M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow20.00K-5.75M-51.04M-144.83M-176.36M-188.89M-187.03M-159.16M-3.47M-171.27M
Investing Cash Flow-144.71M-144.71M-144.71M-147.14M215.34M-117.43M-1.03M-110.97M29.02M156.36M
Financing Cash Flow40.00K6.00M300.86M321.58M312.54M3.33M117.09M190.15M-11.49M6.42M
Capital Expenditure3.49M3.49M21.21M6.57M24.88M1.62M475.00K0079.00K
Free Cash Flow20.00K-5.75M-72.25M-151.40M-201.24M-190.51M-187.51M-159.16M-3.47M-171.34M
FCF to OCF100.00%100.00%141.55%104.53%114.11%100.86%100.25%100.00%100.00%100.05%

Earnings

Report DateOct 11, 2018Mar 22, 2019May 14, 2019Aug 8, 2019Nov 12, 2019Mar 24, 2020May 12, 2020Aug 11, 2020Nov 10, 2020Feb 25, 2021May 6, 2021Aug 9, 2021Nov 8, 2021Mar 3, 2022May 10, 2022Aug 9, 2022Nov 3, 2022Mar 17, 2023May 9, 2023Aug 8, 2023Nov 9, 2023Mar 5, 2024May 7, 2024Aug 12, 2024Nov 7, 2024Mar 3, 2025May 15, 2025Aug 5, 2025Nov 5, 2025Mar 13, 2026May 15, 2026Aug 13, 2026Nov 4, 2026
EPS Estimate0.00-1.00-0.58-0.43-0.68-0.86-0.75-0.86-0.85-0.79-0.74-0.76-0.77-0.74-0.76-0.69-0.66-0.62-0.54-0.50-0.27-0.21-0.190.27-0.14-0.17-0.18-0.18-0.19-0.18-0.17-0.10-5.54
EPS Actual-0.93-18.23-0.90-0.74-0.80-0.89-0.87-1.00-0.80-0.88-0.78-0.80-0.80-0.74-0.76-0.74-0.65-0.59-0.52-0.45-0.21-0.21-0.190.22-0.14-0.15-0.16-0.17-0.21-0.21-0.20-0.20-
Surprise--1723.00%-55.17%-72.09%-17.65%-3.49%-16.00%-16.28%5.88%-11.39%-5.41%-5.26%-3.90%0.00%0.00%-7.25%1.52%4.84%3.70%10.00%22.22%0.00%0.00%-18.52%0.00%10.71%11.11%5.56%-10.53%-13.51%-17.65%-100.00%-
Timing-After-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap66.91M
Enterprise Value49.99M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.26
Price / Book2.66
EPS-52.73
Book Value-0.192
Revenue (TTM)53.29M
Gross Profit (TTM)53.29M
EBITDA-158.60M
Profit Margin-235.00%
Operating Margin-282.25%
Return on Equity-783.37%
Return on Assets-62.39%
Shares Outstanding6.12M
Shares Float3.83M
Beta2.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 9 analystsTarget 82.48
  • Strong Buy
    4
  • Buy
    3
  • Hold
    2

Ownership Breakdown

Institutions
85.73%
Insiders
1.43%
Retail / Other
12.84%

Top Institutional Holders

  • D. E. Shaw & Co LP
    40.96M8.38%
  • Worth Venture Partners, LLC
    25.02M5.12%
  • Kalehua Capital Management LLC
    17.71M3.62%
  • BlackRock Inc
    16.83M3.44%
  • GSA Capital Partners LLP
    14.99M3.07%
  • AQR Capital Management LLC
    10.13M2.07%
  • Vanguard Capital Management, LLC
    9.39M1.92%
  • ARCH VENTURE CORP
    8.06M1.65%
  • Octagon Capital Advisors LP
    7.75M1.59%
  • Two Sigma Investments LLC
    7.43M1.52%
  • Samsara BioCapital, LLC
    7.22M1.48%
  • Balyasny Asset Management LLC
    5.92M1.21%
  • CI Private Wealth LLC
    5.63M1.15%
  • Acadian Asset Management LLC
    5.28M1.08%
  • Siren, L.L.C.
    5.21M1.07%
  • 683 Capital Management LLC
    5.00M1.02%
  • Hillhouse Capital Advisors, Ltd.
    4.97M1.02%
  • Geode Capital Management, LLC
    4.94M1.01%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    6.91M2.96%
  • iShares Biotechnology ETF
    3.36M1.44%

Stock Splits

  • Sep 11, 20261:80